693 related articles for article (PubMed ID: 37268866)
21. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India.
Gupta D; Gupta N; Singh N; Prinja S
JCO Glob Oncol; 2024 Feb; 10():e2300260. PubMed ID: 38359374
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract][Full Text] [Related]
24. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
25. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.
Zhang M; Zheng B; Yang W; Jiang H; Sun X; Zhao Z; Li G; Dong H
Clin Med Insights Oncol; 2024; 18():11795549241257234. PubMed ID: 38827520
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
28. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
Tao Y; Zhou Y; Tang L; Chen H; Feng Y; Shi Y
Invest New Drugs; 2022 Aug; 40(4):831-840. PubMed ID: 35435628
[TBL] [Abstract][Full Text] [Related]
29. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
31. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
32. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
33. Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
Kongnakorn T; Sarri G; Freitag A; Marczell K; Kazmierska P; Masters E; Pawar V; Zhang X
Pharmacoeconomics; 2022 Feb; 40(2):183-201. PubMed ID: 34595671
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
35. Indirect comparisons of brigatinib and alectinib for front-line
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
[TBL] [Abstract][Full Text] [Related]
36. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
Carlson JJ; Canestaro W; Ravelo A; Wong W
J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
[TBL] [Abstract][Full Text] [Related]
38. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Carlson JJ; Suh K; Orfanos P; Wong W
Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]